Avalon Pharma profit up 21% to SAR 97M in 2025; Q4 at SAR 44.5M

04/03/2026 Argaam Exclusive

Content Summary:

Loading data...

Comments Analysis:

Positive: 0%
Neutral: 0%
Negative: 0%
Comments Summary:Loading data...
Please note that this news summary has been generated using artificial intelligence. It is recommended to review the original sources for complete details and to verify the accuracy of the information.

Middle East Pharmaceutical Industries Co. (Avalon Pharma) posted a net profit of SAR 97 million for 2025, a rise of 21% from SAR 79.9 million a year earlier.



Financials (M)

Item 2024 2025 Change‬
Revenues 394.00 460.48 16.9 %
Gross Income 243.36 286.84 17.9 %
Operating Income 91.03 108.41 19.1 %
Net Income 79.85 97.01 21.5 %
Average Shares 20.00 20.00 -
Earnings Per Share before unusual items (Riyals) 3.99 4.85 21.5 %
EPS (Riyal) 3.99 4.85 21.5 %

The profit growth was attributed to a 16.87% increase in revenue to SAR 460.48 million compared to the previous year, driven by higher sales through pharmacies and modern trade channels, supported by continued expansion in government tenders and exports, improved channel mix, disciplined execution, and active portfolio management.

 

Private sector revenues rose 15.56% year-on-year (YoY) to SAR 310 million (67% of total sales), backed by strategic agreements with major pharmacy chains and hospitals, while institutional (government) revenues rose 23.45% YoY to SAR 93 million (20% of total sales) mainly due to winning government tenders.

 

International (export) revenues climbed 13.98% YoY to SAR 57 million (13% of total sales), reflecting ongoing expansion in markets including Iraq, Libya, and Oman.

 

Growth was further supported by strong performance across key therapeutic categories, with pain management up 80% YoY, cardiometabolic treatments up 28%, respiratory products up 16%, and dermatology up 12%.

 

Gross profit margin improved on the back of a better product mix, economies of scale from higher production activity. Gross profit rose on improved margins and lower expenses.

 

This was partially offset by higher selling, distribution, and general and administrative expenses, largely due to continued investments in sales and marketing activities, talent acquisition and development, and other growth-supporting initiatives.



Current Quarter Comparison (M)

Compared With The
Item Q4 2024 Q4 2025 Change‬
Revenues 135.99 137.51 1.1 %
Gross Income 89.15 90.47 1.5 %
Operating Income 47.49 46.83 (1.4 %)
Net Income 44.81 44.52 (0.6 %)
Average Shares 20.00 20.00 -
Earnings Per Share before unusual items (Riyal) 2.24 2.23 (0.6 %)
EPS (Riyal) 2.24 2.23 (0.6 %)

The company's Q4 2025 net profit inched down 0.6% to SAR 44.52 million, compared to SAR 44.81 million a year earlier.

 

Sequentially, net earnings soared 437.8% from SAR 8.28 million in Q3 2025.

 

Shareholders' equity, excluding minority interest, rose to SAR 416.24 million as of Dec. 31, 2025, compared to SAR 368.21 million in the prior-year period.

 

Attached Documents

 

View more financial results

 

View other reports

Share Price

Middle East Pharmaceutical Industries Co.
102.80
3.30 3.32 %

Middle East Pharmaceutical Industries Co. (AVALON PHARMA)

More


Financial Ratios
Current
Market Cap (M Riyal) 2,056.00
Enterprise Value (EV) (M Riyal) 2,085.00
Shares Outstanding ((M)) 20.00
EPS ( Riyal) (TTM) 4.85
Book Value (BV) ( Riyal) 20.81
Par Value ( Riyal) 10.00
Recurring P/E 21.19
P/E (TTM) 21.19
Price/book 4.94
Return on Average Assets (%) (TTM) 17.2
Return on Average Equity (%) (TTM) 24.7
EV/adj EBITDA -
EV/Revenues 4.53
more

Kindly, you can view the full report by subscribing to the

The report contains the details of the financial statements, The most important financial indicators, Historical information, Charts, and Forecasts of experts.

Contact Us (+966)-92000-7759

Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
loader Train
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Popular Links

Quick Links

Join Us

Argaam.com Copyright © 2026, Argaam Investment, All Rights Reserved
Call Request